



Antidote Treatment – Nerve Agent, Autoinjector

ATNAA

Description

The Food and Drug Administration-approved ATNAA (NSN 6505-01-362-7427) is a 2-chambered autoinjector used for the intramuscular injection of the nerve agent antidotes atropine and 2-pralidoxime chloride (2-PAM) through the same needle. The ATNAA is administered after onset of symptoms to treat nerve agent toxicity. The ATNAA is a replacement for the currently fielded MARK I Nerve Agent Antidote Kit that delivers the same two drugs but requires two separate autoinjectors.



Mission

Treat the effects of nerve agent exposure to allow warfighters to survive an otherwise lethal exposure.

Capabilities

- Treats the effects of nerve agent intoxication.
- Improvements over the Mark I: Easier to use, delivers antidotes faster, takes less space, and costs less.

Users

US Navy, US Marine Corps, US Army, US Air Force

Status

Sustainment

This Fact Sheet was cleared for public release on 6/25/2012.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@us.army.mil,
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919